Cargando…

Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications

Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively treated through the administration of antibiotics (e.g., colistimethate sodium). Chronic infection with Pseudomonas aeruginosa is one of the most significant events in the pathogenesis of cystic fibrosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Marcus, Twigg, Matthew, Sheridan, Emer A., Hardy, John G., Elborn, J. Stuart, Taggart, Clifford C., Scott, Christopher J., Migaud, Marie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722511/
https://www.ncbi.nlm.nih.gov/pubmed/31382357
http://dx.doi.org/10.3390/pharmaceutics11080379
_version_ 1783448554253058048
author Hill, Marcus
Twigg, Matthew
Sheridan, Emer A.
Hardy, John G.
Elborn, J. Stuart
Taggart, Clifford C.
Scott, Christopher J.
Migaud, Marie E.
author_facet Hill, Marcus
Twigg, Matthew
Sheridan, Emer A.
Hardy, John G.
Elborn, J. Stuart
Taggart, Clifford C.
Scott, Christopher J.
Migaud, Marie E.
author_sort Hill, Marcus
collection PubMed
description Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively treated through the administration of antibiotics (e.g., colistimethate sodium). Chronic infection with Pseudomonas aeruginosa is one of the most significant events in the pathogenesis of cystic fibrosis, and tobramycin is the treatment of choice for those patients with chronic P. aeruginosa infection who are deteriorating despite regular administration of colistimethate sodium. Effective treatment can be challenging due to the accumulation of thickened mucus in the pulmonary environment, and here we describe the results of our investigation into the development of alginate/chitosan particles prepared via precipitation for such environments. Tobramycin loading and release from the alginate/chitosan particles was investigated, with evidence of both uptake and release of sufficient tobramycin to inhibit P. aeruginosa in vitro. Functionalisation of the alginate/chitosan particles with secretory leukocyte protease inhibitor (SLPI) was shown to help inhibit the inflammatory response associated with lung infections (via inhibition of neutrophil elastase activity) and enhance their interaction with cystic fibrosis mucus (assayed via reduction of the depth of particle penetration into the mucus) in vitro, which have prospects to enhance their efficacy in vivo.
format Online
Article
Text
id pubmed-6722511
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67225112019-09-10 Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications Hill, Marcus Twigg, Matthew Sheridan, Emer A. Hardy, John G. Elborn, J. Stuart Taggart, Clifford C. Scott, Christopher J. Migaud, Marie E. Pharmaceutics Communication Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively treated through the administration of antibiotics (e.g., colistimethate sodium). Chronic infection with Pseudomonas aeruginosa is one of the most significant events in the pathogenesis of cystic fibrosis, and tobramycin is the treatment of choice for those patients with chronic P. aeruginosa infection who are deteriorating despite regular administration of colistimethate sodium. Effective treatment can be challenging due to the accumulation of thickened mucus in the pulmonary environment, and here we describe the results of our investigation into the development of alginate/chitosan particles prepared via precipitation for such environments. Tobramycin loading and release from the alginate/chitosan particles was investigated, with evidence of both uptake and release of sufficient tobramycin to inhibit P. aeruginosa in vitro. Functionalisation of the alginate/chitosan particles with secretory leukocyte protease inhibitor (SLPI) was shown to help inhibit the inflammatory response associated with lung infections (via inhibition of neutrophil elastase activity) and enhance their interaction with cystic fibrosis mucus (assayed via reduction of the depth of particle penetration into the mucus) in vitro, which have prospects to enhance their efficacy in vivo. MDPI 2019-08-02 /pmc/articles/PMC6722511/ /pubmed/31382357 http://dx.doi.org/10.3390/pharmaceutics11080379 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Hill, Marcus
Twigg, Matthew
Sheridan, Emer A.
Hardy, John G.
Elborn, J. Stuart
Taggart, Clifford C.
Scott, Christopher J.
Migaud, Marie E.
Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications
title Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications
title_full Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications
title_fullStr Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications
title_full_unstemmed Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications
title_short Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications
title_sort alginate/chitosan particle-based drug delivery systems for pulmonary applications
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722511/
https://www.ncbi.nlm.nih.gov/pubmed/31382357
http://dx.doi.org/10.3390/pharmaceutics11080379
work_keys_str_mv AT hillmarcus alginatechitosanparticlebaseddrugdeliverysystemsforpulmonaryapplications
AT twiggmatthew alginatechitosanparticlebaseddrugdeliverysystemsforpulmonaryapplications
AT sheridanemera alginatechitosanparticlebaseddrugdeliverysystemsforpulmonaryapplications
AT hardyjohng alginatechitosanparticlebaseddrugdeliverysystemsforpulmonaryapplications
AT elbornjstuart alginatechitosanparticlebaseddrugdeliverysystemsforpulmonaryapplications
AT taggartcliffordc alginatechitosanparticlebaseddrugdeliverysystemsforpulmonaryapplications
AT scottchristopherj alginatechitosanparticlebaseddrugdeliverysystemsforpulmonaryapplications
AT migaudmariee alginatechitosanparticlebaseddrugdeliverysystemsforpulmonaryapplications